| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/31/2006 | US20060194730 Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| 08/31/2006 | US20060194729 Method of promoting natural bypass |
| 08/31/2006 | US20060194728 Following completion of surfactant replacement therapy for respiratory distress syndrome, administering additional pulmonary surfactant to infant, thereby treating infant at risk of developing bronchopulmonary dysplasia; additional pulmonary surfactant is administered on or after day 3 of life of infant |
| 08/31/2006 | US20060194727 Prevention and reduction of blood loss |
| 08/31/2006 | US20060194726 Administering into cartilage such as meniscus or an intervertebral disc or intosynovial fluid surrounding cartilage a bone morphogenic protein; osteoarthritis, disc degeneration, and anterior cruciate ligament injuries; sustained release |
| 08/31/2006 | US20060194725 Methods of treating disease with random copolymers |
| 08/31/2006 | US20060194724 Methods and systems for nerve regeneration |
| 08/31/2006 | US20060194723 Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement |
| 08/31/2006 | US20060194722 orally administering to human a composition comprising salmon calcitonin in free or salt form and a delivery agent selected from N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), N-(10-[2-hydroxybenzoyl]amino)decanoic acid (SNAD), N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAG), and disodium salts |
| 08/31/2006 | US20060194721 Tissue regeneration |
| 08/31/2006 | US20060194720 Human glucagon-like peptide-1 (GLP-1) derivatives absorbed highly via a mucous membrane in the oral cavity, lung, nose or intestines; for therapy of non-insulin dependent diabetes muellitus, insulin dependent diabetes mellitus and/or obesity |
| 08/31/2006 | US20060194719 Stabilized exendin-4 compounds |
| 08/31/2006 | US20060194718 treating peptic ulcers caused by Helicobacter pylori infection; e.g. wheat germ lectins |
| 08/31/2006 | US20060194717 reduced tissue accumulation of the glycopeptide antibiotic, reduced nephrotoxicity and reduced histamine release; side effect reduction |
| 08/31/2006 | US20060194716 Polyacid glycopeptide derivatives |
| 08/31/2006 | US20060194715 Proteins encoded by ble genes and antibiotics from the bleomycin family |
| 08/31/2006 | US20060194714 Novel depsipeptides and process for preparing same |
| 08/31/2006 | US20060194713 Methods for treating delirium using glucocorticoid receptor-specific antagonists |
| 08/31/2006 | US20060194339 Isolated biopolymer marker peptide; using mass spectrometry to determine markers predictive of insulin resistance |
| 08/31/2006 | US20060194318 Cultured cd14+ antigen presenting cells |
| 08/31/2006 | US20060194293 Rb1 gene induced protein (rb1cc1) and gene |
| 08/31/2006 | US20060194292 Contains insulin-like growth factor-I, insulin-like growth factor binding protein 3 and integrin-binding domain of vitronectin ; wound healing; surgical implant, prosthesis, scaffold, wound or burn dressing |
| 08/31/2006 | US20060194291 Comprising human immunoglobulin g1 fc region, which mediates antibody-dependent cell-mediated cytotoxicity in presence of effector cells more effectively; binds fc gamma receptor iii with better affinity |
| 08/31/2006 | US20060194290 Polypeptide variants with altered effector function |
| 08/31/2006 | US20060194287 Chemokine-binding protein and methods of use |
| 08/31/2006 | US20060194286 Apo-2LI and Apo-3 polypeptides |
| 08/31/2006 | US20060194283 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 08/31/2006 | US20060194275 Transporter and ion channels |
| 08/31/2006 | US20060194264 Affinity based system for detecting particulates in a fluid |
| 08/31/2006 | US20060194257 MECP2E1 gene |
| 08/31/2006 | US20060194244 Uses of a chemokine receptor for inhibiting HIV-1 infection |
| 08/31/2006 | US20060194233 Ligand of the protein "beacon" |
| 08/31/2006 | US20060194204 Gene expressed in prostate cancer, methods and use thereof |
| 08/31/2006 | US20060194201 Autism gene |
| 08/31/2006 | US20060193965 Oilseed processing |
| 08/31/2006 | US20060193920 Nanoparticulate compositions of mitogen-activated protein (map) kinase inhibitors |
| 08/31/2006 | US20060193919 Comprises a metal-containing anti-cancer drug being adsorbed onto or included in oxidized porous carbon nanohorns; novel drug carrier, which is excellent in characteristics of drug adsorption or inclusion and releasing properties |
| 08/31/2006 | US20060193918 Solvent/polymer solutions as suspension vehicles |
| 08/31/2006 | US20060193917 potentiating radiotherapy of lung cancer treatment by administering 4(5)-nitro-L-histidine to increase anticarcinogenic agent synergistic effect |
| 08/31/2006 | US20060193916 Formulations of peptides for periodontal and dental treatments |
| 08/31/2006 | US20060193906 Sugar-modified liposome and products comprising the liposome |
| 08/31/2006 | US20060193905 Direct cellular energy delivery system |
| 08/31/2006 | US20060193887 Medical devices having nanoporous bonding layers |
| 08/31/2006 | US20060193884 terpolymer comprising polyoxyalkylene copolymer, polycaprolactone, with copolymerizable monomers such as glycolide, lactide, p-dioxanone and trimethylene carbonate; surgical sutures; for coating medical equipment |
| 08/31/2006 | US20060193871 transmission and, or amplification of signal; oral or enteric administering, dissolving, absorption; peptide yy; obesity therapy |
| 08/31/2006 | US20060193870 Compositions and methods for the therapy and diagnosis of colon cancer |
| 08/31/2006 | US20060193868 graphitic nanotubes substituted with chemical moieties or upon which certain cyclic compounds are adsorbed; complex structures comprised of such functionalized fibrils linked to one another; introducing functional groups onto the surface of such fibrils |
| 08/31/2006 | US20060193866 H pylori antigens |
| 08/31/2006 | US20060193864 Conversion of apoptotic proteins |
| 08/31/2006 | US20060193861 Tumor necrosis factor receptors 6 alpha & 6 beta |
| 08/31/2006 | US20060193859 Methods of Treatment Using Antibodies to Neutrokine-alpha |
| 08/31/2006 | US20060193858 Full-lenth, isolated polypeptide comprising a polypeptide sequence of human SRC-like adaptor protein |
| 08/31/2006 | US20060193853 Combinations of growth-and hormone-regulating factors for the treatment of neoplasia |
| 08/31/2006 | US20060193852 immunotherapy, preferably against B-cell malignancies such as non-Hodgkin lymphoma; single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen; domains are arranged in the order VLCD19-VHCD19-VHCD3-VLCD3; vector; cell |
| 08/31/2006 | US20060193851 Human anti-factor IX/IXa antibodies |
| 08/31/2006 | US20060193847 Peptides for inhibiting retroviruses |
| 08/31/2006 | US20060193846 Carrier with solid fibrinogen and solid thrombin |
| 08/31/2006 | US20060193845 Combination therapy for controlled carbohydrate digestion |
| 08/31/2006 | US20060193844 Methods for enzyme inhibition |
| 08/31/2006 | US20060193843 Thermostable enzyme compositions |
| 08/31/2006 | US20060193840 Perivascular mesenchymal precursor cell induced blood vessel formation |
| 08/31/2006 | US20060193838 Method and composition for treating diabetes |
| 08/31/2006 | US20060193836 Method and composition for repairing heart tissue |
| 08/31/2006 | US20060193834 Antiprotozal composition |
| 08/31/2006 | US20060193833 Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof |
| 08/31/2006 | US20060193831 administering to the striatum or substantia nigra of the an amount of pleiotrophin suitable for promoting graft survival and reinnervation of the tissues of the brain and survival of dopaminergic neuron grafts administered to the patient; treats Alzheimer, Parkinson, Huntingtons diesease |
| 08/31/2006 | US20060193828 Expression enhancer for HM1.24 antigen |
| 08/31/2006 | US20060193827 Methods using TCF -II |
| 08/31/2006 | US20060193826 Methods to mobilize progenitor/stem cells |
| 08/31/2006 | US20060193825 Complex of polypeptide and macromolecular carrier |
| 08/31/2006 | US20060193824 Methods for the treatment of infectious and inflammatory airway diseases |
| 08/31/2006 | US20060193790 Promoting whole body health |
| 08/31/2006 | US20060193786 Pharmaceutical composition for intranasal administration containing a CGRP antagonist |
| 08/31/2006 | US20060193778 Receptor-mediated uptake of peptides that bind the human transferrin receptor |
| 08/31/2006 | US20060193775 Embedder compositions and methods for detecting and killing cells in acidic areas of tumors |
| 08/31/2006 | US20060193774 Transporter compositions and methods for detecting and killing cells in acidic areas of tumors |
| 08/31/2006 | US20060193773 Peptide-based compounds for use as targeting vectors that bind to receptors associated with angiogenesis; may thus be used for diagnosis or therapy of, for example, malignant diseases, heart diseases, endometriosis, inflammation-related diseases, rheumatoid arthritis and Kaposi's s sarcoma |
| 08/31/2006 | US20060193770 Bioassay of measuring tyrosine-kinase ligand, tumor necrosis factor and transforming growth factor level, before administering the myelosuppressive agent to the patient; use in optimizing treatment and avoiding toxic effects |
| 08/31/2006 | US20060192966 Gas sensors |
| 08/31/2006 | US20060191375 Methods for fine powder formation |
| 08/31/2006 | DE19952957B4 Modulare Transportsysteme für molekulare Substanzen und deren Herstellung und Verwendung Modular Transport systems for molecular substances and their production and use |
| 08/31/2006 | DE102005009099A1 New camptothecin-peptide derivatives, useful for treating cancer |
| 08/31/2006 | DE102005009084A1 New anthracyclin-peptide derivatives, useful for treating cancer, especially of the prostate, are cleaved, in the tumor, by prostate-specific antigen to release active antitumor agent and are transported by serum albumen |
| 08/31/2006 | DE102005008994A1 Pharmaceutical preparation used for the diagnosis and/or therapy of e.g. diabetes mellitus comprises a fusion polypeptide, a fusion peptide and a combination preparation containing zinc and organic molecules |
| 08/31/2006 | CA2599439A1 Ykl-40 monoclonal antibody |
| 08/31/2006 | CA2599150A1 Anticancer agent comprising paclitaxel and a diptheria toxin mutant, crm 197 |
| 08/31/2006 | CA2599139A1 Revascularization of ischemic retinal tissue and screening method therefor |
| 08/31/2006 | CA2598924A1 Use of leptin for the prevention of excess body weight and composition containing leptin |
| 08/31/2006 | CA2598864A1 Promoter of regeneration of pancreatic .beta. cell, and promoter of insulin production in pancreatic .beta. cell |
| 08/31/2006 | CA2598823A1 Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| 08/31/2006 | CA2598806A1 Alkyl-glycoside enhanced vaccination |
| 08/31/2006 | CA2598713A1 Nod1 as an anti-tumor agent |
| 08/31/2006 | CA2598688A1 Single branch heparin-binding growth factor analogs |
| 08/31/2006 | CA2598666A1 Intranasal administration of active agents to the central nervous system |
| 08/31/2006 | CA2598492A1 Microglia facilitated amyloidogenesis assay |
| 08/31/2006 | CA2598488A1 Immunogens from uropathogenic escherichia coli |
| 08/31/2006 | CA2598439A1 Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
| 08/31/2006 | CA2598289A1 Tropoelastin for promoting endothelial cell adhesion or migration |
| 08/31/2006 | CA2571982A1 Methods of modulating intracellular degradation rates of toxins |
| 08/30/2006 | EP1696036A1 Use of recombinant adeno-associated virus in the manufacture of a medicament for gene therapy via muscle cells |